REPL

Replimune Group, Inc. (REPL) | Rumor.io

Replimune Group

REPL

Attention (50-day avg)0%

Attention rank (50-day avg)#974

Bullish sentiment (50-day avg)35%

Price to earnings ratio-3.71

Market capitalization1.2B

Earnings per share-3.15

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-313.9M

Social

What share of all stock conversation is about REPL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% -0.02	0% 0

Aug 21

Replimune Group's stock price fell by 72.3% over two trading days after the FDA rejected its RP1 application in April 2026.
A new case was filed against Replimune Group, alleging that the company overstated the strength of its RP1 FDA application and failed to disclose key study design concerns.
The company's stock price is expected to close badly, with some users predicting a sell-off and shorting opportunities, citing a decline in message volume and bearish sentiment.

Generated by AI

Sentiment

Of the messages about REPL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	61.54% +16.54	76.92% +46.49	40.7% -24.27
Bearish	0%	38.46% -16.54	23.08% -46.49	59.3% +24.27

Bullish· Aug 12

The stock has been on a strong upward trajectory, with some users predicting it will reach triple digits within 10 years, and others anticipating a potential buyout offer that could drive the price to $20-30.
The company's approval and the addition of new revenue streams, such as its inclusion in small cap indexes and initial trial results of RP2, are expected to be major catalysts for the stock's continued growth.
Despite initial concerns about dilution following the company's offering, the stock has maintained its strength, with some users attributing this to the lack of punishment for the dilution and the addition of new bullish signals, including a 13D filing about the warrants.

Bearish· Aug 19

Replimune Group's sales are expected to be minimal, making the company worthless.
The company's sales will be heavily impacted by Moderna's recent news, causing a significant decline in stock price.
Replimune Group is likely to be put out of business due to its inability to compete with Moderna and Merck, requiring significant additional funding.

Generated by AI

Topics

Of the messages about REPL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	57.89%	67.74%	28.88%
Technical Analysis	0%	0%	6.45%	2.56%
Controversies	0%	0%	0%	7.63%
Analysts	0%	42.11%	25.81%	32.31%
Macro	0%	0%	0%	28.61%
Earnings	0%	0%	0%	0%

Announcements· Aug 10

Replimune Group, Inc. (REPL) has priced an underwritten offering of about 9.7 million shares at $12.06 per share and pre-funded warrants to buy roughly 2.7 million shares at $12.0599 per pre-funded warrant, for gross proceeds of about $150 million.
The offering is seen as a strategic move made possible by the recent FDA approval of TUDRIQEV, and the market has quickly priced in the news, with REPL shares surging.
The financing is expected to fund a substantial portion of the launch/Phase 3 runway before launch and without taking a distressed price, changing the funding picture and reducing the financing overhang for the company.

Technical Analysis· Jul 30

$REPL has shown a massive move with a potential range to $9+ and is watching for a break and base over pre-market double top.
The stock has formed higher lows with an oversold RSI, and a textbook short/long flip is setting up with a massive gap overhead.
$REPL is currently in a gap on the daily chart, with the 200-day SMA at $10.8 and a next resistance level in the 8.92 to 9.25 range.

Generated by AI

Community

Of the messages about REPL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	80%	86.21%	68.02%	55.25%
Newcomers	20%	13.79%	31.98%	44.75%

Regulars· Aug 19

The recent approval of Amtagvi/Keytruda by Merck and the potential approval of V490 could create a "flywheel" for Iovance, complementing its existing pipeline and increasing its market value.
The Moderna/Merck news is expected to significantly impact Replimune's sales, with some predicting that the company will have 0 to no sales and will ultimately end up in the "biotech graveyard".
Replimune's stock price is expected to drop, with some predicting it will reach $13, and some are holding short positions or buying put options to profit from the expected decline.

Newcomers· Aug 19

Newcomers are focused on the potential decline of Replimune Group, Inc., with some predicting a 25% drop on open and others expecting it to "just die already."
The company is facing a securities fraud case, and some are speculating that the Moderna news will become a major problem for Replimune in its core indication.
New investors are also concerned about Replimune's financial situation, with one user suggesting that the CEO should offer shares today to avoid the company being "put out of business."

Generated by AI

News

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

13d agoMorningstar

REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact SueWallSt

19d agoMorningstar

Replimune at cantor healthcare conference: careful launch, broad pipeline

20d agoInvesting.com

REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026

20d agoMorningstar

REPL DEADLINE: SueWallSt Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline

26d agoMorningstar

Replimune to Present at the Cantor Global Healthcare Conference 2026

WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10 at 9:10 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be availa

27d agoYahoo Finance

Also Discussed

Investors talking about REPL also mention

#	Name	Attention
1	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
2	Candel Therapeutics, Inc.CADL	0.02%+0.01
3	Grace Therapeutics, Inc.GRCE	0%new
4	IO Biotech, Inc.IOBT	0%0
5	Abivax SAABVX	0.01%-0.01
6	Regenxbio Inc.RGNX	0%+0
7	Capricor Therapeutics, Inc.CAPR	0.34%+0.25
8	Revolution Medicines, Inc.RVMD	0.01%-0.01
9	SWTX - SpringWorks Therapeutics, Inc.	——
10	Travere Therapeutics Inc.TVTX	0%0

Replimune Group, Inc.

Healthcare
Biotechnology

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors. The company’s product pipeline includes therapies built on its proprietary RPx platform, with candidates aimed at multiple cancer settings. Replimune Group, Inc. serves the oncology market by advancing biologic approaches intended to complement or expand existing cancer treatment options. Headquartered in Woburn, Massachusetts, and founded in 2015, the company operates in the United States and the United Kingdom, with an emphasis on research, development, and commercialization of cancer immunotherapy programs.

Website

Location

500 Unicorn Park Drive

Woburn, MA, 01801

United States

Social

What share of all stock conversation is about REPL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% -0.02	0% 0

Aug 21

Replimune Group's stock price fell by 72.3% over two trading days after the FDA rejected its RP1 application in April 2026.
A new case was filed against Replimune Group, alleging that the company overstated the strength of its RP1 FDA application and failed to disclose key study design concerns.
The company's stock price is expected to close badly, with some users predicting a sell-off and shorting opportunities, citing a decline in message volume and bearish sentiment.

Generated by AI

Sentiment

Of the messages about REPL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	61.54% +16.54	76.92% +46.49	40.7% -24.27
Bearish	0%	38.46% -16.54	23.08% -46.49	59.3% +24.27

Bullish· Aug 12

The stock has been on a strong upward trajectory, with some users predicting it will reach triple digits within 10 years, and others anticipating a potential buyout offer that could drive the price to $20-30.
The company's approval and the addition of new revenue streams, such as its inclusion in small cap indexes and initial trial results of RP2, are expected to be major catalysts for the stock's continued growth.
Despite initial concerns about dilution following the company's offering, the stock has maintained its strength, with some users attributing this to the lack of punishment for the dilution and the addition of new bullish signals, including a 13D filing about the warrants.

Bearish· Aug 19

Replimune Group's sales are expected to be minimal, making the company worthless.
The company's sales will be heavily impacted by Moderna's recent news, causing a significant decline in stock price.
Replimune Group is likely to be put out of business due to its inability to compete with Moderna and Merck, requiring significant additional funding.

Generated by AI

Topics

Of the messages about REPL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	57.89%	67.74%	28.88%
Technical Analysis	0%	0%	6.45%	2.56%
Controversies	0%	0%	0%	7.63%
Analysts	0%	42.11%	25.81%	32.31%
Macro	0%	0%	0%	28.61%
Earnings	0%	0%	0%	0%

Announcements· Aug 10

Replimune Group, Inc. (REPL) has priced an underwritten offering of about 9.7 million shares at $12.06 per share and pre-funded warrants to buy roughly 2.7 million shares at $12.0599 per pre-funded warrant, for gross proceeds of about $150 million.
The offering is seen as a strategic move made possible by the recent FDA approval of TUDRIQEV, and the market has quickly priced in the news, with REPL shares surging.
The financing is expected to fund a substantial portion of the launch/Phase 3 runway before launch and without taking a distressed price, changing the funding picture and reducing the financing overhang for the company.

Technical Analysis· Jul 30

$REPL has shown a massive move with a potential range to $9+ and is watching for a break and base over pre-market double top.
The stock has formed higher lows with an oversold RSI, and a textbook short/long flip is setting up with a massive gap overhead.
$REPL is currently in a gap on the daily chart, with the 200-day SMA at $10.8 and a next resistance level in the 8.92 to 9.25 range.

Generated by AI

Community

Of the messages about REPL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	80%	86.21%	68.02%	55.25%
Newcomers	20%	13.79%	31.98%	44.75%

Regulars· Aug 19

The recent approval of Amtagvi/Keytruda by Merck and the potential approval of V490 could create a "flywheel" for Iovance, complementing its existing pipeline and increasing its market value.
The Moderna/Merck news is expected to significantly impact Replimune's sales, with some predicting that the company will have 0 to no sales and will ultimately end up in the "biotech graveyard".
Replimune's stock price is expected to drop, with some predicting it will reach $13, and some are holding short positions or buying put options to profit from the expected decline.

Newcomers· Aug 19

Newcomers are focused on the potential decline of Replimune Group, Inc., with some predicting a 25% drop on open and others expecting it to "just die already."
The company is facing a securities fraud case, and some are speculating that the Moderna news will become a major problem for Replimune in its core indication.
New investors are also concerned about Replimune's financial situation, with one user suggesting that the CEO should offer shares today to avoid the company being "put out of business."

Generated by AI

Replimune Group

Social

Aug 21

Bullish· Aug 12

Bearish· Aug 19

Announcements· Aug 10

Technical Analysis· Jul 30

Regulars· Aug 19

Newcomers· Aug 19

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact SueWallSt

Replimune at cantor healthcare conference: careful launch, broad pipeline

REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026

REPL DEADLINE: SueWallSt Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline

Replimune to Present at the Cantor Global Healthcare Conference 2026

Also Discussed

Replimune Group, Inc.

Company Information

Location

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact SueWallSt

Replimune at cantor healthcare conference: careful launch, broad pipeline

REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026

REPL DEADLINE: SueWallSt Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline

Replimune to Present at the Cantor Global Healthcare Conference 2026

Also Discussed

Social

Aug 21

Bullish· Aug 12

Bearish· Aug 19

Announcements· Aug 10

Technical Analysis· Jul 30

Regulars· Aug 19

Newcomers· Aug 19